UroGen Pharma (URGN) EBIAT: 2016-2025
Historic EBIAT for UroGen Pharma (URGN) over the last 10 years, with Sep 2025 value amounting to -$33.3 million.
- UroGen Pharma's EBIAT fell 40.87% to -$33.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$164.6 million, marking a year-over-year decrease of 42.70%. This contributed to the annual value of -$126.9 million for FY2024, which is 24.09% down from last year.
- UroGen Pharma's EBIAT amounted to -$33.3 million in Q3 2025, which was up 33.23% from -$49.9 million recorded in Q2 2025.
- UroGen Pharma's 5-year EBIAT high stood at -$21.9 million for Q3 2023, and its period low was -$49.9 million during Q2 2025.
- In the last 3 years, UroGen Pharma's EBIAT had a median value of -$32.3 million in 2024 and averaged -$32.4 million.
- Its EBIAT has fluctuated over the past 5 years, first surged by 30.62% in 2021, then slumped by 49.51% in 2025.
- Quarterly analysis of 5 years shows UroGen Pharma's EBIAT stood at -$28.5 million in 2021, then fell by 1.47% to -$28.9 million in 2022, then increased by 9.88% to -$26.0 million in 2023, then slumped by 44.19% to -$37.5 million in 2024, then crashed by 40.87% to -$33.3 million in 2025.
- Its EBIAT was -$33.3 million in Q3 2025, compared to -$49.9 million in Q2 2025 and -$43.8 million in Q1 2025.